본문 바로가기
  • Home

Inhibitory Effects of 1′,2′-Dihydrorotenone on Osteoclast Differentiation and Bone Resorption In Vitro and In Vivo

Kwang-Jin Kim 1 곽한복 2 최은영 2 오재민 2 최민규 2 이정휴 2 송미진 2 안용환 2 이명수 2 Chang Hoon Lee 2 박성훈 2 김명희 3 김성환 3 박기인 4 김광미 5 김하영 2 문서영 2 김정중 2 채수욱 2

1원광대학교
2원광대학교
3대전 화학연구원
4전북대학교
5초당대학교

Accredited

ABSTRACT

It is important to identify therapeutic compounds with no adverse effects for use in the chemotherapy of patients with bone-related diseases. The aim of this study was to identify a new compound that inhibits osteoclast differentiation and bone resorption. Herein, we examined the effects of 1′,2′-dihydrorotenone on osteoclast differentiation and bone resorption in vitro and in vivo. 1′,2′-dihydrorotenone inhibited receptor activator of NF-κB ligand (RANKL)-induced osteoclast differentiation of cultured bone marrow macrophages (BMMs) in a dosedependent manner. However, 1′,2′-dihydrorotenone did not exert cytotoxic effect on BMMs. 1′,2′-dihydrorotenone suppressed the expression of c-fos and NFATc1 as well as osteoclast-specific genes in BMMs treated with RANKL. Treatment with RANKL inhibited the expression of inhibitors of differentiation/DNA binding (Id)1, 2, and 3; however,in the presence of 1′,2′-dihydrorotenone, RANKL did not suppress the expression of Id1, 2, and 3. Furthermore,1′,2′-dihydrorotenone inhibited bone resorption and considerably attenuated the erosion of trabecular bone induced by lipopolysaccharide treatment. Taken together, these results suggest that 1′,2′-dihydrorotenone has the potential to be applied in therapies for bone-related diseases.

Citation status

* References for papers published after 2023 are currently being built.